

Roberto Chiarle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7930265/publications.pdf>

Version: 2024-02-01

142
papers

9,137
citations

41323

49
h-index

43868

91
g-index

143
all docs

143
docs citations

143
times ranked

13682
citing authors

#	ARTICLE	IF	CITATIONS
1	Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. <i>Blood</i> , 2022, 139, 717-731.	0.6	22
2	Deletion of murine <i>RhoG</i> leads to de-repression of <i>Bcl-6</i> via decreased KAISO levels and accelerates a malignancy phenotype in a murine model of lymphoma. <i>Small GTPases</i> , 2022, 13, 267-281.	0.7	3
3	Congenital anemia reveals distinct targeting mechanisms for master transcription factor GATA1. <i>Blood</i> , 2022, 139, 2534-2546.	0.6	14
4	Rapid next-generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newborn. <i>Blood Advances</i> , 2022, 6, 2893-2896.	2.5	2
5	Frequency and mechanisms of LINE-1 retrotransposon insertions at CRISPR/Cas9 sites. <i>Nature Communications</i> , 2022, 13, .	5.8	30
6	Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. <i>Blood</i> , 2022, 140, 1822-1826.	0.6	8
7	IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	27
8	Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019. <i>Mayo Clinic Proceedings</i> , 2021, 96, 817.	1.4	1
9	Dissecting ELANE neutropenia pathogenicity by human HSC gene editing. <i>Cell Stem Cell</i> , 2021, 28, 833-845.e5.	5.2	23
10	Abstract 1544: Generation of ALK CAR-T cells for neuroblastoma therapy. , 2021, , .		0
11	Solving the chromosome puzzle of aneuploidy in cancer. <i>Genes and Development</i> , 2021, 35, 1073-1075.	2.7	5
12	Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma. <i>Blood Advances</i> , 2021, 5, 5239-5257.	2.5	7
13	CD24/Siglec-10 "Don't Eat Me" Signal Blockade Is a Potential Immunotherapeutic Target in Mantle-Cell Lymphoma. <i>Blood</i> , 2021, 138, 2276-2276.	0.6	8
14	High Levels of miR-7-5p Potentiate Crizotinib-Induced Cytokilling and Autophagic Flux by Targeting RAF1 in NPM-ALK Positive Lymphoma Cells. <i>Cancers</i> , 2020, 12, 2951.	1.7	8
15	A LIBRETTO to orchestrate targeted therapy. <i>Nature Cancer</i> , 2020, 1, 1038-1040.	5.7	1
16	Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma. <i>Lung Cancer</i> , 2020, 146, 366-369.	0.9	11
17	IL10RA Modulates Crizotinib Sensitivity in NPM1-ALK-positive Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2020, 136, 1657-1669.	0.6	22
18	CRISPR/Cas9 Screens Reveal Multiple Layers of B cell CD40 Regulation. <i>Cell Reports</i> , 2019, 28, 1307-1322.e8.	2.9	18

#	ARTICLE	IF	CITATIONS
19	RHO Family GTPases in the Biology of Lymphoma. <i>Cells</i> , 2019, 8, 646.	1.8	26
20	Wiskottâ€ Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. <i>Nature Medicine</i> , 2019, 25, 130-140.	15.2	57
21	Identifying Novel Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2019, 134, 5060-5060.	0.6	0
22	KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. <i>Cell</i> , 2018, 172, 857-868.e15.	13.5	220
23	Comment on â€œALK is a therapeutic target for lethal sepsisâ€ Science Translational Medicine, 2018, 10, .	5.8	7
24	Parp3 promotes long-range end joining in murine cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10076-10081.	3.3	11
25	The CRISPR/Cas9 System as a Tool to Engineer Chromosomal Translocation In Vivo. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1044, 39-48.	0.8	12
26	Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. <i>Cancers</i> , 2018, 10, 62.	1.7	73
27	Phosphatidylinositol 3-kinase Î± blockade increases genomic instability in B cells. <i>Nature</i> , 2017, 542, 489-493.	13.7	105
28	Primary Cutaneous Bâ€Cell Lymphoblastic Lymphoma Arising from a Longâ€Standing Lesion in a Child and Review of the Literature. <i>Pediatric Dermatology</i> , 2017, 34, e182-e186.	0.5	12
29	P3.02a-006 Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1162-S1163.	0.5	0
30	Comprehensive population-based genome sequencing provides insight into hematopoietic regulatory mechanisms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E327-E336.	3.3	39
31	Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2Î± Scaffolding Function. <i>Cancer Cell</i> , 2017, 32, 444-459.e7.	7.7	69
32	Combined immunodeficiency with EBV positive B cell lymphoma and epidermodysplasia verruciformis due to a novel homozygous mutation in RASGRP1. <i>Clinical Immunology</i> , 2017, 183, 142-144.	1.4	43
33	A Braf kinase-inactive mutant induces lung adenocarcinoma. <i>Nature</i> , 2017, 548, 239-243.	13.7	85
34	Developmentallyâ€faithful and effective human erythropoiesis in immunodeficient and <i>Kit</i> mutant mice. <i>American Journal of Hematology</i> , 2017, 92, E513-E519.	2.0	20
35	Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns. <i>Vaccines</i> , 2017, 5, 20.	2.1	6
36	Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization. <i>Oncotarget</i> , 2017, 8, 18680-18698.	0.8	24

#	ARTICLE	IF	CITATIONS
37	Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017, 8, 3274-3288.	0.8	13
38	Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 92265-92274.	0.8	17
39	Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma. <i>Cancer Research</i> , 2016, 76, 6095-6106.	0.4	30
40	Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system. <i>Nature Communications</i> , 2016, 7, 10934.	5.8	57
41	Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice. <i>Blood</i> , 2016, 127, 1297-1306.	0.6	26
42	Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. <i>Oncogene</i> , 2016, 35, 3854-3865.	2.6	37
43	Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1. <i>Oncotarget</i> , 2016, 7, 33316-33330.	0.8	35
44	Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes. <i>ELife</i> , 2016, 5, .	2.8	5
45	Myc and Bcl2 Overexpression and Traslocation Assessed By Immunohistochemistry (IHC) and FISH: Retrospective Analysis in a Series of De Novo DLBCL Homogeneously Treated with Rituximab-CHOP. <i>Blood</i> , 2016, 128, 5305-5305.	0.6	0
46	Advances in cancer immunology and cancer immunotherapy. <i>Discovery Medicine</i> , 2016, 21, 125-33.	0.5	58
47	The anaplastic lymphoma kinase as an oncogene in solid tumors. <i>Frontiers in Bioscience - Scholar</i> , 2015, 7, 269-282.	0.8	5
48	A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of Boron Neutron Capture Therapy in the lung cancer treatment. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 741-750.	1.7	51
49	The BRAF Pseudogene Functions as a Competitive Endogenous RNA and Induces Lymphoma In Vivo. <i>Cell</i> , 2015, 161, 319-332.	13.5	293
50	Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. <i>Cancer Immunology Research</i> , 2015, 3, 1333-1343.	1.6	42
51	PI3Kdelta Inhibitors Increase Genomic Instability By Upregulating Aid Expression. <i>Blood</i> , 2015, 126, 164-164.	0.6	1
52	FBXO11, a Regulator of BCL6 Stability, Is Recurrently Mutated in Burkitt Lymphoma. <i>Blood</i> , 2015, 126, 3673-3673.	0.6	0
53	De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab (R)-CHOP: Definition and Validation of a Prognostic Score Model Based on MYC, BCL2 and BCL6 Expression By Immunohistochemistry (IHC). <i>Blood</i> , 2015, 126, 2650-2650.	0.6	0
54	Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma. <i>Blood Cancer Journal</i> , 2014, 4, e249-e249.	2.8	11

#	ARTICLE	IF	CITATIONS
55	ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis. <i>Cancer Research</i> , 2014, 74, 6094-6106.	0.4	45
56	Simple and Rapid In Vivo Generation of Chromosomal Rearrangements using CRISPR/Cas9 Technology. <i>Cell Reports</i> , 2014, 9, 1219-1227.	2.9	186
57	<i>IgH</i> class switching exploits a general property of two DNA breaks to be joined <i>in cis</i> over long chromosomal distances. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 2644-2649.	3.3	33
58	FuseFISH: Robust Detection of Transcribed Gene Fusions in Single Cells. <i>Cell Reports</i> , 2014, 6, 18-23.	2.9	39
59	Modeling Lung Cancer Evolution and Preclinical Response by Orthotopic Mouse Allografts. <i>Cancer Research</i> , 2014, 74, 5978-5988.	0.4	30
60	Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: A tissue micro array-based multicenter study. <i>Lung Cancer</i> , 2014, 85, 191-196.	0.9	32
61	The BRAF Pseudogene Is a Proto-Oncogenic Competitive Endogenous RNA. <i>Blood</i> , 2014, 124, 263-263.	0.6	2
62	STAT3 ^{Δ2} controls inflammatory responses and early tumor onset in skin and colon experimental cancer models. <i>American Journal of Cancer Research</i> , 2014, 4, 484-94.	1.4	14
63	Vaccination With ENO1 DNA Prolongs Survival of Genetically Engineered Mice With Pancreatic Cancer. <i>Gastroenterology</i> , 2013, 144, 1098-1106.	0.6	104
64	Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. <i>Journal of Hematology and Oncology</i> , 2013, 6, 67.	6.9	42
65	STAT3 activity is necessary and sufficient for the development of immune-mediated myocarditis in mice and promotes progression to dilated cardiomyopathy. <i>EMBO Molecular Medicine</i> , 2013, 5, 572-590.	3.3	44
66	Tissue flow cytometry immunophenotyping in the diagnosis and classification of non-Hodgkin's lymphomas: A retrospective evaluation of 1,792 cases. <i>Cytometry Part B - Clinical Cytometry</i> , 2013, 84B, 82-95.	0.7	33
67	Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex. <i>Neoplasia</i> , 2013, 15, 511-517.	2.3	44
68	Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing. <i>Nature Methods</i> , 2013, 10, 361-365.	9.0	409
69	Translocations in Normal B Cells and Cancers. <i>Advances in Immunology</i> , 2013, 117, 39-71.	1.1	7
70	The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. <i>Oncogenesis</i> , 2013, 2, e43-e43.	2.1	27
71	FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. <i>Nature</i> , 2012, 481, 90-93.	13.7	256
72	The battle against ALK resistance: successes and setbacks. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1751-1754.	1.9	15

#	ARTICLE	IF	CITATIONS
73	CALming Down T Cell Acute Leukemia. <i>Cancer Cell</i> , 2012, 21, 449-450.	7.7	4
74	Genome-wide Translocation Sequencing Reveals Mechanisms of Chromosome Breaks and Rearrangements in B Cells. <i>Cell</i> , 2011, 147, 107-119.	13.5	411
75	Genome-wide Translocation Sequencing Reveals Mechanisms of Chromosome Breaks and Rearrangements in B Cells. <i>Cell</i> , 2011, 147, 1640.	13.5	3
76	Mechanisms that Promote and Suppress Chromosomal Translocations in Lymphocytes. <i>Annual Review of Immunology</i> , 2011, 29, 319-350.	9.5	137
77	The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway. <i>Blood</i> , 2011, 117, 6617-6626.	0.6	22
78	Neuroblastoma-targeted Nanoparticles Entrapping siRNA Specifically Knockdown ALK. <i>Molecular Therapy</i> , 2011, 19, 1131-1140.	3.7	56
79	Selective Therapeutic Targeting of the Anaplastic Lymphoma Kinase With Liposomal siRNA Induces Apoptosis and Inhibits Angiogenesis in Neuroblastoma. <i>Molecular Therapy</i> , 2011, 19, 2201-2212.	3.7	57
80	Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. <i>Leukemia and Lymphoma</i> , 2011, 52, 1742-1750.	0.6	17
81	Stat3 is required for anchorage-independent growth and metastasis but not for mammary tumor development downstream of the ErbB2 oncogene. <i>Molecular Carcinogenesis</i> , 2010, 49, 114-120.	1.3	29
82	Expression of IFN γ R2 mutated in a dileucine internalization motif reinstates IFN γ signaling and apoptosis in human T lymphocytes. <i>Immunology Letters</i> , 2010, 134, 17-25.	1.1	12
83	PHOX2B-Mediated Regulation of ALK Expression: In Vitro Identification of a Functional Relationship between Two Genes Involved in Neuroblastoma. <i>PLoS ONE</i> , 2010, 5, e13108.	1.1	40
84	Involvement of Grb2 Adaptor Protein in Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK)-mediated Signaling and Anaplastic Large Cell Lymphoma Growth. <i>Journal of Biological Chemistry</i> , 2010, 285, 26441-26450.	1.6	25
85	The Role of Mechanistic Factors in Promoting Chromosomal Translocations Found in Lymphoid and Other Cancers. <i>Advances in Immunology</i> , 2010, 106, 93-133.	1.1	106
86	MT1-MMP Is Required for Myeloid Cell Fusion via Regulation of Rac1 Signaling. <i>Developmental Cell</i> , 2010, 18, 77-89.	3.1	108
87	NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells. <i>Cancer Research</i> , 2009, 69, 8611-8619.	0.4	86
88	Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?. <i>Hematological Oncology</i> , 2009, 27, 161-170.	0.8	61
89	An integrated humoral and cellular response is elicited in pancreatic cancer by β -enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. <i>International Journal of Cancer</i> , 2009, 125, 639-648.	2.3	115
90	Leukocyte transmigration is modulated by chemokine-mediated PI3K-dependent phosphorylation of vimentin. <i>European Journal of Immunology</i> , 2009, 39, 1136-1146.	1.6	59

#	ARTICLE	IF	CITATIONS
91	Anaplastic lymphoma kinase: an oncogene for tumor vaccination. <i>Journal of Molecular Medicine</i> , 2009, 87, 669-677.	1.7	10
92	IL-6, but not IFN- β , triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing. <i>Leukemia</i> , 2009, 23, 2102-2108.	3.3	31
93	IL-18 Paradox in Pancreatic Carcinoma: Elevated Serum Levels of Free IL-18 are Correlated With Poor Survival. <i>Journal of Immunotherapy</i> , 2009, 32, 920-931.	1.2	42
94	The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL. <i>Blood</i> , 2009, 113, 2776-2790.	0.6	42
95	The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. <i>Nature Medicine</i> , 2008, 14, 676-680.	15.2	112
96	The anaplastic lymphoma kinase in the pathogenesis of cancer. <i>Nature Reviews Cancer</i> , 2008, 8, 11-23.	12.8	792
97	The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation. <i>Cancer Research</i> , 2008, 68, 8899-8907.	0.4	54
98	An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors. <i>Clinical Cancer Research</i> , 2008, 14, 2220-2226.	3.2	15
99	Heat shock protein expression in diabetic nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, F1817-F1824.	1.3	50
100	High Energy Shock Waves (HESW) Increase Paclitaxel Efficacy in a Syngeneic Model of Breast Cancer. <i>Technology in Cancer Research and Treatment</i> , 2008, 7, 117-124.	0.8	12
101	Of alphas and betas: distinct and overlapping functions of STAT3 isoforms. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 6501.	3.0	41
102	Conditional Activation of MET in Differentiated Skeletal Muscle Induces Atrophy. <i>Journal of Biological Chemistry</i> , 2007, 282, 6812-6822.	1.6	24
103	The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration. <i>Cancer Research</i> , 2007, 67, 4278-4286.	0.4	86
104	The Down syndrome critical region protein TTC3 inhibits neuronal differentiation via RhoA and Citron kinase. <i>Journal of Cell Science</i> , 2007, 120, 1859-1867.	1.2	59
105	Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase β . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 14354-14359.	3.3	57
106	In the absence of IGF-1 signaling, IFN- β suppresses human malignant T-cell growth. <i>Blood</i> , 2007, 109, 2496-2504.	0.6	20
107	Autoantibody Signature in Human Ductal Pancreatic Adenocarcinoma. <i>Journal of Proteome Research</i> , 2007, 6, 4025-4031.	1.8	88
108	Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. <i>Clinical and Experimental Immunology</i> , 2007, 149, 504-512.	1.1	83

#	ARTICLE	IF	CITATIONS
109	Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. <i>Blood</i> , 2006, 107, 689-697.	0.6	127
110	Incestuous Paternity Detected by STR-typing of Chorionic Villi Isolated from Archival Formalin-fixed Paraffin-embedded Abortion Material Using Laser Microdissection. <i>Journal of Forensic Sciences</i> , 2006, 51, 90-92.	0.9	25
111	Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and Bcl2A1 as critical target genes. <i>Journal of Clinical Investigation</i> , 2006, 116, 3171-3182.	3.9	139
112	p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. <i>Blood</i> , 2005, 106, 3907-3916.	0.6	72
113	Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. <i>Nature Medicine</i> , 2005, 11, 623-629.	15.2	406
114	RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis. <i>Cancer Gene Therapy</i> , 2005, 12, 456-463.	2.2	34
115	Follicular Origin of a Subset of CD5+ Diffuse Large B-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2005, 124, 182-190.	0.4	18
116	New and Old Functions of STAT3: A Pivotal Target for Individualized Treatment of Cancer. <i>Cell Cycle</i> , 2005, 4, 1131-1133.	1.3	111
117	Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas. <i>American Journal of Clinical Pathology</i> , 2005, 124, 182-90.	0.4	5
118	Role of Pax2 in Apoptosis Resistance and Proinvasive Phenotype of Kaposi's Sarcoma Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 4136-4143.	1.6	42
119	The STAT3 isoforms $\hat{1}\pm$ and $\hat{1}^2$ have unique and specific functions. <i>Nature Immunology</i> , 2004, 5, 401-409.	7.0	202
120	Confocal microscope analysis and tridimensional reconstruction of papillary thyroid carcinoma nuclei. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004, 444, 350-355.	1.4	29
121	Estrogen Receptor $\hat{1}\pm$ Is a Novel Marker Expressed by Follicular Dendritic Cells in Lymph Nodes and Tumor-Associated Lymphoid Infiltrates. <i>American Journal of Pathology</i> , 2003, 163, 1313-1320.	1.9	49
122	NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. <i>Blood</i> , 2003, 101, 1919-1927.	0.6	234
123	In Vivo Interference with Skp1 Function Leads to Genetic Instability and Neoplastic Transformation. <i>Molecular and Cellular Biology</i> , 2002, 22, 8375-8387.	1.1	53
124	S-Phase Kinase-Associated Protein 2 Expression in Non-Hodgkin's Lymphoma Inversely Correlates with p27 Expression and Defines Cells in S Phase. <i>American Journal of Pathology</i> , 2002, 160, 1457-1466.	1.9	94
125	Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. <i>Oncogene</i> , 2002, 21, 1038-1047.	2.6	354
126	Role of the F-box protein Skp2 in lymphomagenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 2515-2520.	3.3	269

#	ARTICLE	IF	CITATIONS
127	Initiation of translation from a downstream in-frame AUG codon on BRCA1 can generate the novel isoform protein Î²BRCA1(17aa). <i>Oncogene</i> , 2000, 19, 2767-2773.	2.6	20
128	Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. <i>Blood</i> , 2000, 95, 619-626.	0.6	199
129	The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. <i>Breast Cancer Research</i> , 2000, 3, 91.	2.2	79
130	Substitutions at Codon 22 of Alzheimer's AÎ² Peptide Induce Diverse Conformational Changes and Apoptotic Effects in Human Cerebral Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2000, 275, 27110-27116.	1.6	178
131	Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia. <i>British Journal of Haematology</i> , 2000, 111, 263-271.	1.2	19
132	CD30 in Normal and Neoplastic Cells. <i>Clinical Immunology</i> , 1999, 90, 157-164.	1.4	158
133	Detection of Immunoglobulin Îµ Light Chain Rearrangements by Polymerase Chain Reaction. <i>American Journal of Pathology</i> , 1999, 155, 355-363.	1.9	60
134	Pure Alveolar Rhabdomyosarcoma of the Corpus Uteri: Description of a Case with Increased Serum Level of CA-125. <i>Gynecologic Oncology</i> , 1997, 66, 320-323.	0.6	26
135	Detection of BCL-6 rearrangements and p53 mutations in malt-lymphomas. , 1997, 56, 206-213.		30
136	p53 Overexpression and Thymoma Prognosis. , 1997, , 47-54.		1
137	p53 expression and proliferative activity predict survival in non-invasive thymomas. , 1996, 69, 180-183.		12
138	Long-term Survival of Thymoma Patients by Histologic Pattern and Proliferative Activity. <i>American Journal of Surgical Pathology</i> , 1995, 19, 918-926.	2.1	28
139	Identification of the Same HRAS1 Mutation in a Primary Minimally Invasive Follicular Carcinoma of the Thyroid Gland and its Bone Metastasis Developed 15 Years Later. <i>Diagnostic Molecular Pathology</i> , 1995, 4, 73-74â€“74.	2.1	11
140	Argyrophilic nucleolar organizer region counts predict survival in thymoma. <i>Cancer</i> , 1994, 74, 1568-1574.	2.0	22
141	Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. , 0, .		3
142	CRISPR/Cas9 Screens Reveal Multiple Layers of B Cell CD40 Regulation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0